Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
CERT
HoldSinkerCertara, Inc. · Healthcare · United States · $1.3B · Avg Vol: $23M/d
COMPANY DESCRIPTION
Certara, Inc. is a global leader in biosimulation software and technology-enabled services, which are critical for optimizing drug discovery, development, and regulatory submissions for pharmaceutical and biotech companies. Its competitive advantage lies in its proprietary, industry-standard modeling and simulation platform, coupled with deep scientific expertise that accelerates R&D and reduces clinical trial costs.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 335.6M | 354.3M | 385.1M | 418.8M | 7.7% | 421.7M | 380.1M | 389.6M | -3.6% |
| EPS | 0.09 | -0.35 | -0.08 | -0.01 | — | -0.14 | — | — | — |
| Shares | 159.5M | 159.8M | 161.0M | 159.1M | -0.2% | 152.5M | — | — | — |
| Debt | 308.1M | 302.6M | 311.9M | 306.0M | -0.2% | 301.9M | — | — | — |
| Equity | 1.1B | 1.0B | 1.1B | 1.1B | -0.5% | — | — | — | — |
| Op CF | 92.5M | 82.8M | 80.5M | 96.3M | 1.3% | 82.9M | — | — | — |
| Inv CF | -27.8M | -79.5M | -112.4M | -26.6M | — | — | — | — | — |
| Fin CF | -7.4M | -9.4M | -21.0M | -64.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CERT are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CERT | Certara, Inc.(you) | $1.3B | 48 | Hold |
| TDOC | Teladoc Health, Inc. | $1.2B | 49 | Hold |
| PHR | Phreesia, Inc. | $751M | 48 | Hold |
| SDGR | Schrödinger, Inc. | $1.5B | 36 | Hold |
| PRVA | Privia Health Group, Inc. | $2.7B | 51 | Hold |
| OMDA | Omada Health, Inc. | $1.5B | 65 | Buy |
| MDRX | Veradigm Inc. | $517M | 51 | Hold |
| OMCL | Omnicell, Inc. | $1.5B | 66 | Buy |
| EVH | Evolent Health, Inc. | $520M | 43 | Hold |
| CARL | Carlsmed, Inc. | $461M | 40 | Hold |
Peer medians: ROE -30.8% · P/E 27.0x · Gross margin 58.1%